Clinical Trials Logo

Acute Ischemic Stroke clinical trials

View clinical trials related to Acute Ischemic Stroke.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05671874 Suspended - Clinical trials for Traumatic Brain Injury

Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI

Start date: March 28, 2023
Phase: N/A
Study type: Interventional

The goal is to pilot test a highly accessible, web-based, pragmatic, scalable intervention to overcome ongoing problems with high stakes decision-making by surrogate decision-makers of patients in ICUs with severe acute brain injury (SABI), including those with moderate-severe traumatic brain injury, large hemispheric acute ischemic stroke and intracerebral hemorrhage.

NCT ID: NCT05592054 Suspended - Clinical trials for Acute Ischemic Stroke

Proximal TEmporary oCclusion Using Balloon Guide Catheter for Mechanical Thrombectomy

PROTECT-MT
Start date: November 20, 2022
Phase: N/A
Study type: Interventional

A multi-center, prospective, randomized, open-label, blinded endpoint assessment (PROBE) clinical trial of endovascular treatment among selected AIS.

NCT ID: NCT04984577 Suspended - Clinical trials for Acute Ischemic Stroke

Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

Start date: November 15, 2021
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner. The study is also to examine the safety of compound Edaravone Injection for the AIS patients.

NCT ID: NCT04891913 Suspended - Clinical trials for Acute Ischemic Stroke

SY007 in Patients With Acute Ischemic Stroke

Start date: July 1, 2023
Phase: Phase 1
Study type: Interventional

This Phase 1b multiple center, randomized, double-blind, placebo-controlled study is a dose escalation trial evaluating the safety, tolerability, PK characteristics and efficacy of SY-007 after injection in acute ischemicstroke patients. The immunogenicity of SY-007 will be evaluated and this study will provide the recommended dosage for subsequent clinical trials.